Table 2.
Overall prevalence of antimicrobial resistance among five major sequence types (STs)
| ST69 | ST73 | ST95 | ST127 | ST131 | |
|---|---|---|---|---|---|
| Antibiotics | Insusceptible isolates, n (%) | ||||
| Imipenem | 0 | 2 (15.4) | 2 (13.3) | 0 | 2 (2.6) |
| Meropenem | 0 | 1 (7.7) | 1 (6.7) | 0 | 1 (1.3) |
| Ertapenem | 0 | 3 (23.1) | 2 (13.3) | 1 (4.5) | 10 (13) |
| Ceftazidime | 8 (33.3) | 2 (15.4) | 4 (26.7) | 4 (18.2) | 59 (76.6) |
| P-valuea | 0.008 | 0.05 | 0.001 | 0.0001 | |
| Cefepime | 2 (8.3) | 3 (23.1) | 0 | 4 (18.2) | 45 (58.4) |
| P-value | 0.002 | 0.001 | 0.0001 | ||
| Cefotaxime | 9 (37.5) | 6 (46.2) | 7 (46.7) | 10 (45.5) | 71 (92.2) |
| P-value | 0.001 | 0.02 | 0.0001 | ||
| Aztreonam | 9 (37.5) | 4 (30.8) | 5 (33.3) | 6 (27.3) | 68 (88.3) |
| P-value | 0.01 | 0.03 | 0.02 | 0.001 | 0.0001 |
| Amoxicillin–clavulanate | 12 (50) | 5 (38.5) | 4 (26.7) | 11 (50) | 46 (59.7) |
| P-value | 0.05 | 0.05 | |||
| Piperacillin–tazobactam | 1 (4.2) | 2 (15.4) | 3 (20) | 2 (9.1) | 13 (16.9) |
| Ampicillin–sulbactam | 2 (8.3) | 5 (38.5) | 3 (20) | 5 (22.7) | 34 (44.2) |
| P-value | 0.004 | 0.002 | |||
| Trimethoprim–sulfamethoxazole | 22 (91.7) | 7 (53.8) | 5 (33.3) | 8 (36.4) | 53 (68.8) |
| P-value | 0.001 | 0.02 | 0.008 | ||
| Ciprofloxacin | 5 (20.8) | 4 (30.8) | 5 (33.3) | 5 (22.7) | 69 (89.6) |
| P-value | 0.0001 | 0.04 | 0.05 | 0.0001 | 0.0001 |
| Levofloxacin | 2 (8.3) | 2 (15.4) | 3 (20) | 4 (18.2) | 68 (88.3) |
| P-value | 0.0001 | 0.007 | 0.01 | 0.001 | 0.0001 |
| Amikacin | 2 (8.3) | 1 (7.7) | 2 (13.3) | 0 | 8 (10.4) |
| Gentamicin | 1 (4.2) | 0 | 2 (13.3) | 2 (9.1) | 34 (44.2) |
| P-value | 0.009 | 0.02 | 0.0001 | ||
| Tobramycin | 3 (12.5) | 1 (7.7) | 0 | 3 (13.6) | 36 (46.8) |
| P-value | 0.006 | 0.0001 | |||
| MDR | 10 (41.7) | 4 (30.8) | 5 (33.3) | 5 (22.7) | 66 (85.7) |
| P-value | 0.03 | 0.05 | 0.0001 | 0.0001 | |
| Resistance score (mean, median) | 3.17, 2.50 | 3.54, 4 | 3, 1 | 2.77, 2 | 7, 7 |
| ESBL phenotype | 9 (37.5) | 6 (46.2) | 7 (46.7) | 10 (45.5) | 71 (92.2) |
| P-value | 0.001 | 0.02 | 0.0001 | ||
Notes:
a
Comparison between each ST with all other STs combined. Bold values indicate significant associations. P-values in rows shown for differences that were statistically significant (P<0.05). Underlining indicates a negative association.
Abbreviations: MDR, multidrug resistance; ESBL, extended spectrum β-lactamase.